IBDEI1FC ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25257,1,2,0)
 ;;=2^V62.89
 ;;^UTILITY(U,$J,358.3,25257,1,5,0)
 ;;=5^PHASE OF LIFE PROBLEMS
 ;;^UTILITY(U,$J,358.3,25257,2)
 ;;=^303724
 ;;^UTILITY(U,$J,358.3,25258,0)
 ;;=V61.12^^144^1577^34
 ;;^UTILITY(U,$J,358.3,25258,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25258,1,2,0)
 ;;=2^V61.12
 ;;^UTILITY(U,$J,358.3,25258,1,5,0)
 ;;=5^PHYS ABUSE BY ADULT
 ;;^UTILITY(U,$J,358.3,25258,2)
 ;;=^303717
 ;;^UTILITY(U,$J,358.3,25259,0)
 ;;=V68.1^^144^1577^35
 ;;^UTILITY(U,$J,358.3,25259,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25259,1,2,0)
 ;;=2^V68.1
 ;;^UTILITY(U,$J,358.3,25259,1,5,0)
 ;;=5^PRESCRIPTION REFILL
 ;;^UTILITY(U,$J,358.3,25259,2)
 ;;=^295585
 ;;^UTILITY(U,$J,358.3,25260,0)
 ;;=V62.89^^144^1577^36
 ;;^UTILITY(U,$J,358.3,25260,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25260,1,2,0)
 ;;=2^V62.89
 ;;^UTILITY(U,$J,358.3,25260,1,5,0)
 ;;=5^PSYCHOLOGICAL STRESS
 ;;^UTILITY(U,$J,358.3,25260,2)
 ;;=^87822
 ;;^UTILITY(U,$J,358.3,25261,0)
 ;;=V62.9^^144^1577^37
 ;;^UTILITY(U,$J,358.3,25261,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25261,1,2,0)
 ;;=2^V62.9
 ;;^UTILITY(U,$J,358.3,25261,1,5,0)
 ;;=5^PSYCHOSOCIAL CIRCUM NOS
 ;;^UTILITY(U,$J,358.3,25261,2)
 ;;=^295551
 ;;^UTILITY(U,$J,358.3,25262,0)
 ;;=V62.89^^144^1577^39
 ;;^UTILITY(U,$J,358.3,25262,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25262,1,2,0)
 ;;=2^V62.89
 ;;^UTILITY(U,$J,358.3,25262,1,5,0)
 ;;=5^RELIGIOUS PROBLEMS
 ;;^UTILITY(U,$J,358.3,25262,2)
 ;;=^303725
 ;;^UTILITY(U,$J,358.3,25263,0)
 ;;=V61.9^^144^1577^38
 ;;^UTILITY(U,$J,358.3,25263,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25263,1,2,0)
 ;;=2^V61.9
 ;;^UTILITY(U,$J,358.3,25263,1,5,0)
 ;;=5^RELATIONAL PROBLEM
 ;;^UTILITY(U,$J,358.3,25263,2)
 ;;=^303721
 ;;^UTILITY(U,$J,358.3,25264,0)
 ;;=V65.42^^144^1577^40
 ;;^UTILITY(U,$J,358.3,25264,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25264,1,2,0)
 ;;=2^V65.42
 ;;^UTILITY(U,$J,358.3,25264,1,5,0)
 ;;=5^SUBSTANCE ABUSE COUNSELING
 ;;^UTILITY(U,$J,358.3,25264,2)
 ;;=^303467
 ;;^UTILITY(U,$J,358.3,25265,0)
 ;;=V62.0^^144^1577^41
 ;;^UTILITY(U,$J,358.3,25265,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25265,1,2,0)
 ;;=2^V62.0
 ;;^UTILITY(U,$J,358.3,25265,1,5,0)
 ;;=5^UNEMPLOYMENT
 ;;^UTILITY(U,$J,358.3,25265,2)
 ;;=^123545
 ;;^UTILITY(U,$J,358.3,25266,0)
 ;;=V65.49^^144^1577^31
 ;;^UTILITY(U,$J,358.3,25266,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25266,1,2,0)
 ;;=2^V65.49
 ;;^UTILITY(U,$J,358.3,25266,1,5,0)
 ;;=5^OTHER SPECIFIED COUNSELING
 ;;^UTILITY(U,$J,358.3,25266,2)
 ;;=^303471
 ;;^UTILITY(U,$J,358.3,25267,0)
 ;;=V58.61^^144^1577^18
 ;;^UTILITY(U,$J,358.3,25267,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25267,1,2,0)
 ;;=2^V58.61
 ;;^UTILITY(U,$J,358.3,25267,1,5,0)
 ;;=5^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,25267,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,25268,0)
 ;;=V58.62^^144^1577^20
 ;;^UTILITY(U,$J,358.3,25268,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25268,1,2,0)
 ;;=2^V58.62
 ;;^UTILITY(U,$J,358.3,25268,1,5,0)
 ;;=5^L/T (CURRENT) USE ANTIBIOTIC
 ;;^UTILITY(U,$J,358.3,25268,2)
 ;;=^321546
 ;;^UTILITY(U,$J,358.3,25269,0)
 ;;=V58.63^^144^1577^22
 ;;^UTILITY(U,$J,358.3,25269,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25269,1,2,0)
 ;;=2^V58.63
 ;;^UTILITY(U,$J,358.3,25269,1,5,0)
 ;;=5^LNG USE ANTIPLTE/THRMBTC
 ;;^UTILITY(U,$J,358.3,25269,2)
 ;;=^329978
 ;;^UTILITY(U,$J,358.3,25270,0)
 ;;=V58.64^^144^1577^23
 ;;^UTILITY(U,$J,358.3,25270,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25270,1,2,0)
 ;;=2^V58.64
 ;;^UTILITY(U,$J,358.3,25270,1,5,0)
 ;;=5^LONG-TERM ANTI-INFLAMTRY
 ;;^UTILITY(U,$J,358.3,25270,2)
 ;;=^329979
 ;;
 ;;$END ROU IBDEI1FC
